Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (481-490 of 578) with videos related to

Pageof 58
Sort By:
The New England Journal of Medicine|December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Virchows Archiv : an International Journal of Pathology|February 19, 2021
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinomaNicole Concin, Carien L Creutzberg, Ignace Vergote, et al.
The New England Journal of Medicine|October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
BMJ (Clinical Research Ed.)|August 1, 2020
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort studyBen Van Calster, Lil Valentin, Wouter Froyman, et al.
The New England Journal of Medicine|July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerIgnace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Carcinogenesis|October 4, 2011
Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer StudyCatherine S Healey, Shahana Ahmed, , et al.
Science Translational Medicine|March 20, 2020
Strong vaccine responses during chemotherapy are associated with prolonged cancer survivalCornelis J M Melief, Marij J P Welters, Ignace Vergote, et al.
Journal of the National Cancer Institute|June 20, 2013
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluationAlain G Zeimet, Daniel Reimer, Monica Huszar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian CancerRachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Pageof 58

Showing results (481-490 of 578) with videos related to

Sort By:
Pageof 58
The New England Journal of Medicine|December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Virchows Archiv : an International Journal of Pathology|February 19, 2021
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinomaNicole Concin, Carien L Creutzberg, Ignace Vergote, et al.
The New England Journal of Medicine|October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
BMJ (Clinical Research Ed.)|August 1, 2020
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort studyBen Van Calster, Lil Valentin, Wouter Froyman, et al.
The New England Journal of Medicine|July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerIgnace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.
Carcinogenesis|October 4, 2011
Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer StudyCatherine S Healey, Shahana Ahmed, , et al.
Science Translational Medicine|March 20, 2020
Strong vaccine responses during chemotherapy are associated with prolonged cancer survivalCornelis J M Melief, Marij J P Welters, Ignace Vergote, et al.
Journal of the National Cancer Institute|June 20, 2013
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluationAlain G Zeimet, Daniel Reimer, Monica Huszar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian CancerRachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
Pageof 58